Portal de investigação
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- D'Amico, F
- Solitano, V
- Aletaha, D
- Hart, A
- Selmi, C
- Ng, SC
- Al Awadhi, S
- Choy, E
- Schulze-Koops, H
- Bossuyt, P
- Olivera, PA
- Kotze, PG
- Ghosh, S
- Peyrin-Biroulet, L
- Danese, S
Unidades de investigação
Abstract
Several efforts have been made to improve the available therapeutic armamentarium of patients with immunemediated inflammatory disorders (IMIDs) leading to the development of biobetters. To date, there is no commonly accepted definition of biobetters. Sixteen physicians with expertise in the field of IMIDs from eleven countries attended a virtual international consensus meeting to provide for the first time a definition of biobetter and to identify unmet needs on this topic. Improvements in clinical outcomes and drug pharmacology were considered crucial for the definition of biobetters, while safety profile and patient acceptability were not. In addition, an appropriate balance between clinical outcomes and costs and a shared decision between physicians and patients should guide the decision to use a biobetter. Clinical studies are required to validate the biobetter definition and to investigate their role in the management of patients with IMIDs.
Dados da publicação
- ISSN/ISSNe:
- 1568-9972, 1873-0183
- Tipo:
- Review
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Autoimmunity Reviews Elsevier
Citações Recebidas na Web of Science: 8
Citações Recebidas na Scopus: 18
Documentos
- Não há documentos
Filiações
Keywords
- Immune-mediated inflammatory disorders; Biobetters; Definition; Consensus
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
D'Amico F,Solitano V,Aletaha D,Hart A,Magro F,Selmi C,Ng SC,Al Awadhi S,Choy E,Schulze H,Bossuyt P,Olivera PA,Kotze PG,Ghosh S,Peyrin L,Danese S. Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmun. Rev. 2021. 20(7):102849. IF:17,390. (1).
